Navigation Links
Varian Medical Systems Spotlights TrueBeam Treatment System for First Time in Europe at ESTRO 2010, September 12-16, Barcelona
Date:9/10/2010

BARCELONA, Spain, Sept. 10 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) is spotlighting its new TrueBeam™ medical linear accelerator for fast, powerful and efficient cancer treatments at the European Society for Therapeutic Radiology and Oncology exhibition in Barcelona next week. A fully-featured TrueBeam system will be the centerpiece of Varian's booth at the annual ESTRO meeting (Booth No. 320).

TrueBeam uses a multitude of technical innovations to dynamically synchronize imaging, patient positioning, motion management, and treatment delivery.  Designed to be a best-in-class and versatile platform, TrueBeam can be used for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy.  The product line includes TrueBeam STx, specially configured for advanced radiosurgery.

With its high intensity mode, TrueBeam can deliver doses at up to 2400 MU/min, more than twice as fast as any other machine for either radiotherapy or radiosurgery. Planning of such rapid treatments is fully supported in the latest version of Varian's Eclipse™ treatment planning system that will also be demonstrated on the Varian booth.

Also on display will be Varian's new Gated RapidArc capability, which enables the use of RapidArc technology in combination with respiratory gating – a process of turning the beam on and off in synchrony with the patient's breathing – during either radiotherapy or radiosurgery. This technology helps to improve the precision of treatment delivery by compensating for tumor motion. Gated RapidArc is available as an upgrade for Trilogy® and Clinac® iX accelerators.  

Varian's UNIQUE™ low energy medical linear accelerator for fast, affordable image-guided RapidArc IMRT treatments in international clinics, will also be on display on the Varian booth, along with the latest version of the company's ARIA® oncology information management software.

Varian's Particle Therapy group will be introducing its fully-integrated ProBeam™ proton therapy system at the show. The ProBeam system incorporates imaging, gating, robotic patient positioning, treatment planning and oncology information software to enhance treatment quality for patients and workflow efficiency for clinicians. Also on show will be the latest in Varian's range of brachytherapy afterloaders and software.

"Varian is at the forefront of technology advances that enable clinicians to benefit patients by delivering faster and more efficient treatments," says Rolf Staehelin, head of Varian's Oncology Systems marketing in Europe.  "With major introductions such as TrueBeam and Gated RapidArc and with a series of ancillary events that focus on the very latest in advanced radiotherapy treatment capabilities, we are looking forward to sharing our excitement about these developments with the radiation oncology community. All the innovations on display at ESTRO are clinically-viable and commercially available today."  

TrueBeam Spotlighted in Series of ESTRO Events

The world's first TrueBeam treatment took place at Zurich University Hospital in Switzerland in April and Professor Urs Luetolf, the hospital's head of radiation oncology, will be presenting his team's latest results at an Emerging Technologies Symposium at ESTRO on September 14th Professor Ben Slotman of VU University Medical Center in Amsterdam, Netherlands, will also be presenting, while Professor John Adler, Varian's chief of new clinical applications, will talk about 'The Future of Radiosurgery and Stereotactic Body Radiotherapy'.

Another highlight at ESTRO 2010 will be a TrueBeam Technologies Night at the Institut Catala d'Oncologia (ICO) in Barcelona, one of the first ten centers in Europe to be equipped with a TrueBeam system.  The device is currently being installed at ICO and will be clinical later this year. Professor Ferran Guedea, head of radiation oncology at ICO, will act as moderator at the Emerging Technologies Symposium.

Editorial contact: Neil Madle, Varian Medical Systems, +44 7786 526068

About Varian Medical Systems

Varian Medical Systems, Inc., of Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection. Varian Medical Systems employs approximately 5,200 people who are located at manufacturing sites in North America, Europe, and China and approximately 70 sales and support offices around the world. For more information, visit http://www.varian.com.


'/>"/>
SOURCE Varian Medical Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. First Patient Enrolled in Europe in Ovature Phase III Ovarian Cancer Trial
2. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
3. Clinical Studies of OvaRex in Advanced Ovarian Cancer Fail to Meet Primary Endpoint
4. Northwest Biotherapeutics Conducting Ovarian Cancer Clinical Trial With DCVax(R)-L at University of Pennsylvania
5. EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers
6. BioNumerik Commences Global Phase III Ovarian Cancer Trial on Novel Anticancer Drug Candidate Known as Karenitecin(R)
7. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
8. Vermillions Biomarkers Prove Beneficial in Identifying Women With Ovarian Cancer and Detecting Early-Stage Disease
9. BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
10. BiPar Sciences Expands Phase 2 Clinical Trials of BSI-201, a Novel DNA Repair Inhibitor, in Ovarian Cancer
11. Join NPRs David Ewing Duncan, Author Jessica Queller and a Panel of Medical and Legal Experts in a 90-Minute Webcast on Genetic Testing, Genomic Medicine and Breast & Ovarian Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2016)... Ill. , Dec. 5, 2016 For ... score on the 2017 Human Rights Campaign Foundation,s ... The CEI is a national benchmarking tool used to ... bisexual, and transgender (LGBT) employee equality. For ... Survey to help companies gauge their equality efforts, culture ...
(Date:12/5/2016)... 2016 Research and Markets has announced the addition ... to 2021" report to their offering. ... , , The global spinal ... 2021, at a CAGR of 5.3% from 2016 to 2021. Factors such ... cases, increasing government spending on healthcare, and rising income levels are propelling ...
(Date:12/5/2016)... , December 5, 2016 PharmaBoardroom today releases ... . ... This report offers companies, investors, policymakers, and stakeholders crucial insight ... of Europe , home to some of the world,s ... pharmaceutical companies in Novartis and Roche, and with a number one ranking ...
Breaking Medicine Technology:
(Date:12/5/2016)... ... ... Shah MD, MBA has joined the Retina Group of New York (RGONY) specializing ... M. Maisel, MD and has been providing tertiary medical and surgical retinal care on Long ... expectations amongst her peers. Growing up in a family of doctors, Dr. Shah emulated ...
(Date:12/5/2016)... ... December 05, 2016 , ... ... ensure moisture measurements are consistently correct. However, regular performance testing is often ... TOLEDO offers a solution: SmartCal™ . This innovative test substance offers ...
(Date:12/5/2016)... ... December 05, 2016 , ... A newly ... significantly improves the reproducibility and accuracy of placing precordial electrodes with little cognitive ... Over the last 60 years, studies have shown that single electrode misplacement is ...
(Date:12/4/2016)... ... December 03, 2016 , ... "Perfect Harmony ... more tools allowing FCPX editors to create professional looking video in a matter ... Perfect Harmony contains a beautifully designed 3D environment for placing in personal media. ...
(Date:12/4/2016)... ... December 03, 2016 , ... ... Company in the Dallas area” Tuesday evening at the 26th Annual SMU Cox ... by SMU's Cox School’s Caruth Institute for Entrepreneurship. Dallas 100™, co-founded by the ...
Breaking Medicine News(10 mins):